If a recent New York Times piece is any guide, direct-to-consumer genetic testing may have more accuracy problems than we thought. Reporter Kira Peikoff ordered three simultaneous tests of her genome from 23andme, Genetic Testing Laboratories, and Pathway Genomics — and the results varied more widely than you might think. According to 23andme, she had an elevated risk of psoriasis, with a lifetime risk of 20.2 percent, but GTL put her lifetime risk at only two percent, well below average. Both firms showed her Type 2 diabetes risk as slightly below the general population, but described it as "decreased" and "medium" respectively, two very different interpretations. It's a reminder of how far genetic testing services still have to go on the accuracy front, over a month after 23andme was blasted by the FDA for marketing their products without approval.
We'll email you a reset link.
If you signed up using a 3rd party account like Facebook or Twitter, please login with it instead.
Choose an available username to complete sign up.
In order to provide our users with a better overall experience, we ask for more information from Facebook when using it to login so that we can learn more about our audience and provide you with the best possible experience. We do not store specific user data and the sharing of it is not required to login with Facebook.